The Compensation Committee of the Board of Directors of Ligand Pharmaceuticals Incorporated approved a promotion for Mr. Matthew Korenberg to Executive Vice President, Finance and Chief Financial Officer and for Mr. charles s. berkman to Senior Vice President, General Counsel and Secretary.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85.77 USD | +0.56% | +6.73% | +20.09% |
May. 13 | Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing | MT |
May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.09% | 1.54B | |
+31.37% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.83% | 239B | |
+9.93% | 211B | |
-6.95% | 203B | |
+10.77% | 171B | |
+0.10% | 163B |
- Stock Market
- Equities
- LGND Stock
- News Ligand Pharmaceuticals Incorporated
- Ligand Pharmaceuticals Incorporated Announces Executive Changes